Work

PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials

Year: 2021

Type: review

Study design: Systematic Review

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.04.023

Authors: P.-M. Morice, I. Ray-Coquard, K.N. Moore, V. Diéras, J. Alexandre

Institutions: Inserm, Centre François Baclesse, Cancers et Préventions, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers, Université de Caen Normandie, Centre Léon Bérard, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, University of Oklahoma, Centre Eugène Marquis, Centre Hospitalier Universitaire de Caen Normandie

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Pfizer, AstraZeneca, AbbVie, Daiichi-Sankyo, Eisai, Merck Sharp and Dohme

OpenAlex ID: W3171458381

FWCI: 0.095

Cites: 6

Cited by: 9

Related to: 10